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Abstract
Kaposi’s sarcoma, a virus-associated neoplasm, can be treated with systemic therapy such interferon
or chemotherapy, although a local alternative is possible in localized disease.
Topical imiquimod is a ligand of the toll-like receptors 7 and 8 on dendritic cells, increasing immune
responses and showing antiviral and antitumoral activities. We report a spectacular response to
imiquimod 5% cream in a patient with classic Kaposi’s sarcoma of the leg.
Introduction
Kaposi’s sarcoma (KS) is a vascular neoplasm with four
clinical subtypes: classic, African immunosuppression-
associated and AIDS-related. All variants have been related
to the eighth human herpes virus (HHV8) [1].
Interferon alpha was used at high dose in AIDS-related KS
and low-dose in classic and endemic KS [2]. Therefore,
topical imiquimod, an immune response modifier with
antiangiogenic properties able to induce interferon-alpha
secretion in situ, could prove a good local treatment for KS
skin lesions [3].
Case presentation
A 57-year-old HIV negative Mediterranean man was
treated with imiquimod 5% cream for purple maculo-
papular cutaneous lesions on the leg that were histologi-
cally consistent with KS (papillary dermal proliferation of
small angulated vessels lined by bland endothelial cells
with an accompanying sparse infiltrate of lymphocytes
and plasma cells).
The treatment protocol consisted of 3 weekly applica-
tions (Monday, Thursday, Saturday) under occlusion for
at least 10 hours (between 10 and 12 hours). During the
first week, the three applications were applied by the
patient under supervision then the cream was self-
administered for the following applications. The toler-
ance was good with no side effects. After twenty weeks,
the purple maculo-papular lesions cleared (complete
clinical response). Six months later the patient is still
disease free.
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Imiquimod 5% cream is a topically active immune
response modifier approved as a treatment for actinic
keratosis, superficial basal cell carcinoma, and external
genital warts. [4] The drug up-regulates cytokine produc-
tion, such as alpha-interferon, tumor necrosis factor alpha
and promotes a T-helper type 1 cell-mediated immune
response. Adverse events reported with imiquimod treat-
ment include local side effects at the application site,
ranging from mild erythema to weeping, crusting, and
erosions. Systemic side effects are exceptional [5].
Concerning the literature, there are only two cases reports
of KS treated by imiquimod and one phase II study. In the
first report, the KS was AIDS-related whereas the second
was a classic Kaposi’s sarcoma [6,7].
In this last report, the patient was treated for classic
Kaposi’s sarcoma of both legs with imiquimod 5% cream
once daily after progression under etoposide at the dose of
50 mg/day. After one year of therapy a complete response
was observed and confirmed according to histopathology
and immunohistochemistry.
The treatment was well tolerated, and the only significant
side effects were flu-like symptoms that disappeared with
the reduction of the dosage. After more than one year of
follow-up, the patient was still disease-free. The tolerance
wasgoodwithonlytransientitchingandflu-likesymptoms.
The phase II trial was conducted by a French team, and
17 patients were enrolled for classic or endemic KS. The
treatment by imiquimod 5% cream was applied under
occlusion three times per week for 24 weeks. Eight patients
(47%) presented objective overall clinical response (2 com-
plete and 6 partial responses). Tumor progression was
noted in 6 patients. The most frequent side effects were
local itching and erythema, seen in 9 patients (53%) [8].
For all the patients, there were no clinically meaningful
changes from baseline in any of the laboratory test values,
physical examinations, or vital sign measurements during
the course of the study. There were no treatment-related
deaths or serious adverse events.
Immunocompetent patients with new and small skin
lesions seem to be ideal patients for treatment by topical
imiquimod. Imiquimod cream offers an attractive alter-
native to locally destructive therapies, with less risk of
pain, ulceration, and residual scarring. Furthermore,
imiquimod can be applied by the patient.
Conclusion
Topical imiquimod seems to be a good local treatment for
Kaposi’s sarcoma skin lesions with a good toxicity profile,
regimens with daily application may offer best clinical
results and should be explored and evaluated concerning
the toxicity.
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